WO2020053509A1

WO2020053509A1 - Analogue compounds of squalamine and their medical use

Info

Publication number: WO2020053509A1
Application number: PCT/FR2019/052064
Authority: WO
Inventors: Olivier Blin; Jean Louis Kraus; Didier Raoult; Jean Michel Brunel; Jean-Marc Rolain; Adèle SAKR
Original assignee: Centre National De La Recherche Scientifique; Assistance Publique - Hopitaux De Marseille; Universite D'aix-Marseille; INSERM (Institut National de la Santé et de la Recherche Médicale); Institut Jean Paoli & Irene Calmettes
Priority date: 2018-09-10
Filing date: 2019-09-09
Publication date: 2020-03-19
Also published as: FR3085679A1; FR3085679B1

Abstract

The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is new analogue compounds of squalamine and their use as a drug, in particular for treating or for preventing bacterial, fungal, viral, parasitic infections, or in the treatment of cancer in humans or animals, as well as pharmaceutical or veterinary compositions comprising said compounds. Finally, the invention relates to the use of these new compounds as disinfecting and/or decontaminating agents.

Description

SIMILAR COMPOUNDS OF SQUALAMINE AND

THEIR MEDICAL USE

Technical area

The present invention relates to a family of squalamine analogues for their use as a medicament, in particular for the treatment or prevention of mycobacterial infections, in particular tuberculosis. The present invention also relates to new analogues of squalamine, their use as a medicament, in particular for the treatment or prevention of bacterial, fungal, viral, parasitic infections or in the treatment of cancer in humans or animals, as well as pharmaceutical or veterinary compositions comprising them. Finally, the invention relates to the use of these new compounds as a disinfecting and / or decontaminating agent.

State of the art

Mycobacteria are aerobic bacilli whose walls, rich in lipids, give them resistance to antiseptic agents and certain antibiotics. Among mycobacteria, we find in particular those responsible for tuberculosis: Mycobacterium tuberculosis and Mycobacterium africanum, present mainly in sub-Saharan Africa; those responsible for leprosy: Mycobacterium leprae, and atypical mycobacteria such as Mycobacterium avium capable of causing infections in patients infected with HIV (Human Immunodeficiency Virus).

More specifically, tuberculosis is an infectious communicable disease caused by Mycobacterium tuberculosis (Koch's bacillus). It most often affects the lungs and is characterized by a cough accompanied by sputum, chest pain, fever and night sweats [1] It represents one of the most deadly infectious pathologies worldwide [2] About one one third of the world's population has latent tuberculosis [3] These people have been infected with bacillus but are not sick and are therefore not contagious. Throughout their lifetime, these subjects have a 5% to 15% risk of developing tuberculosis [3]

The treatment of tuberculosis generally consists in administering to the sick patient a combination of 4 anti-tuberculosis drugs for a duration of 6 months [1] Compliance, that is to say the ability of infected patients to comply with the medical treatment prescribed to them, remains difficult, however, insofar as this treatment is spread over a long period of time and requires a particular organization of on the part of the patient. In addition, the slightest deviation from the prescribed medical protocol can have serious consequences and in particular lead to the ineffectiveness of the treatment and / or relapse of the patient or even the selection of strains resistant to the treatment initially envisaged. In these cases, it is then necessary to seek new alternatives to shorter-term anti-tuberculosis treatment.

Squalamine, the structure of which is recalled below, is a water-soluble aminosterol isolated for the first time in 1993 by Professor Michael Zasloff This molecule has demonstrated powerful anti-angiogenic and antimicrobial activities against a wide range of bacteria including bacteria Gram positive (+) (Staphylococcus aureus, Enterococcus faecalis), Gram negative bacteria (-) (Pseudomonas aeruginosa, Escherichia coli), fungi (Candida albicans) and protozoa [4-6]

Squalamine

The natural source of squalamine is however limited, and its complex and costly chemical synthesis. New aminosteroid compounds derived from squalamine have thus been proposed to replace squalamine [7] These molecules exhibit antibacterial activities similar to those of squalamine, in particular towards certain Gram positive bacteria (+) and certain Gram negative bacteria ( -). They act according to a detergent-type physicochemical action mechanism by causing the wall of Gram-positive bacteria to burst, or by disrupting the outer membrane of Gram-negative bacteria [8]

These aminosteroid compounds, in particular compounds n ° 2 and n ° 3 disclosed in the article Ghodbane et al. [9], moreover, unlike squalamine, have an activity on non-tuberculous mycobacteria such as M. abscessus, M. massiliense, M. chelonae, M. immunogenum, M. bolletii, M. avium avium, M. avium intracellulare and M. avium hominissuis.

In a letter to the publisher of the journal Tuberculosis in 2013, Walker and Houston hypothesized that these molecules could be potential anti-tuberculosis agents [10]. Following this letter, the antibacterial activity of squalamine as well as that of some of its aminosteroid derivatives against mycobacteria, and in particular against Mycobacterium tuberculosis, was tested in 2013 by Ghodbane et al. by the Bactec method in liquid medium [9] The results of this study show that none of the envisaged compounds has activity on Mycobacterium tuberculosis (MIC> 100 pg / mL).

In 2015, Asmar and Drancourt tested the efficacy of squalamine as an active compound in a decontamination protocol which would allow Mycobacterium tuberculosis to be isolated from sputum, while eliminating other contaminating bacteria [11] But this molecule has not could not remove all the contaminants.

Following this report of ineffectiveness of squalamine towards Koch bacillus, no other squalamine derivative has been described as being active against Mycobacterium tuberculosis.

Another example of a dangerous mycobacterium for humans and animals is Mycobacterium xenopi. Present in the environment and in water distribution networks, this mycobacterium has been recognized as responsible for epidemics of bone infections in several patients who underwent surgery at the sports clinic between 1988 and 1993 and whose operation had involved the use of poorly sterilized surgical equipment contaminated with this bacteria [12]

L. Djouhri-Bouktab et al., J. Antimicrob. Chemother, 2011, 66, 1306-130 [13] discloses the use for skin decolonization of Staphylococcus aureus of squalamine and one of its aminosterol derivatives in which the group carrying the hydrogen sulfate function has been replaced by a chain polyamine comprising 4 nitrogen atoms.

WO 2011/067501 discloses the use of squalamine and certain analogous compounds for local topical application for cutaneous-mucosal decolonization of Staphylococcus aureus.

WO 2013/104849 discloses the use of squalamine and certain analogous compounds as a disinfecting agent, in particular against bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa or even yeasts like Candida albicans.

WO 2016/142922 discloses 1 ^'' use in the treatment of bacterial, fungal, viral, parasitic and in the treatment of cancer in the human or animal-derived compounds squalamine in which the hydroxyl group has been replaced by an ether function and in which the hydrogen sulphate group has been eliminated.

None of these documents discloses the use of a squalamine-like compound as a drug in the treatment and / or prevention of infections with a mycobacterium.

There remains a need to provide compounds which are active as antibacterial agents against mycobacteria and in particular against Mycobacterium tuberculosis and Mycobacterium xenopi, and whose chemical structure is different from that of known active compounds. Resistance to known antibiotics appears regularly. It is important to have new molecules to meet the needs of patients.

In particular, there remains the need to provide compounds which can be used to prevent or treat mycobacterial infections, in particular due to Mycobacterium tuberculosis, and whose structure is different from that of the compounds currently used in this application.

There also remains a need to provide compounds which can be used as a disinfecting, sterilizing or decontaminating agent to reduce or eliminate contamination by mycobacteria, in particular by Mycobacterium tuberculosis and by Mycobacterium xenopi, on the surface of inert objects.

Surprisingly, it has been discovered that certain aminosteroid compounds, in particular certain derivatives of squalamine, exhibit an inhibitory activity against mycobacteria, in particular Mycobacterium tuberculosis.

Summary of the invention

The invention relates first of all to a compound chosen from:

- the compounds of formula (P) below, and

- their pharmaceutically acceptable salts,

in which Ri and R ₂ are independently chosen from the groups of formula - (CR3R ₄ ) _n - [X- (CR5R6) _m ] _P -NR8R9 in which:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group; a C ₆ -C ₁₂ aryl group,

- the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ -NHR _S _I0 with s an integer ranging from 1 to 5 and Rio a hydrogen atom, an alkyl group Ci -C ₂ group or an aryl C ₆ -C _2, and

- the groups R and R ₉ , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group or R and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms, m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -,

- the Ru and R groups _{| 2} , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group,

for use as a medicament in the treatment and / or prevention of infections with a mycobacterium in humans or animals, preferably in humans.

Preferably, the compound according to the invention is chosen from:

- the compounds of formula (I) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

- the groups R and R ₉ , identical or different, are chosen from: a hydrogen atom; a C 1 -C ₂ alkyl group or R and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

Advantageously, the bacteria responsible for the infection defined above is chosen from Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium abscessus, Mycobacterium massiliense, Mycobacterium chelonae, Mycobacterium immunogenum, Mycobacterium bolletii, Mycobacterium avium avcium acium bacteria xenopi, from preferably chosen from Mycobacterium tuberculosis and Mycobacterium africanum, even more preferably is Mycobacterium tuberculosis.

Preferably, in the groups Ri and R ₂ , 1 <n + mxp <50, more preferentially 5 <n + mxp <20, even more preferentially l0 £ n + mxp <15.

Preferably, the groups Ri and R ₂ are identical.

Preferably, the groups R ₃ to R ₆ are chosen, independently, from a hydrogen atom and an alkyl group in Ci-Ci ₂ , preferably in C i -C 10.

Even more preferably, the groups R ₃ to R <5 are hydrogen atoms.

According to one embodiment, p is strictly greater than 0 in at least one of the groups Ri and R _2.

According to a first variant of this embodiment, X represents an oxygen atom.

Preferably, according to this variant, at least one of the groups -NHRi and - NHR ₂ is chosen from:

According to a second variant of this embodiment, X represents a group of formula -NR ₇ -, preferably X represents a group -NH-.

According to a preferred embodiment, p is equal to 0 in Ri and in R ₂ .

According to one embodiment, the groups R and R ₉ form, together, a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms.

Preferably, according to this embodiment, at least one of the groups - NHRi and --NHR ₂ is chosen from:

According to a preferred embodiment, R and R ₉ are chosen, independently, from a hydrogen atom and a Ci-Ci ₂ alkyl group.

According to a first variant of this embodiment, the groups R and R ₉ are hydrogen atoms.

According to a second variant of this embodiment, at least one of the groups R and R ₉ is an alkyl group in Ci-Ci ₂ , preferably R and R ₉ are two alkyl groups in Ci-Ci ₂ .

According to a particular embodiment, the compound according to the invention is in the form of a water-soluble salt, preferably in the form of a hydrochloride salt, hydrobromide, triflate, phosphate, lactate, succinate, sulfate or dichloroacetate.

Advantageously, the compound according to the invention is chosen from the compounds of formula (1), (2), (3), (4) and (5) below:

A subject of the invention is also the use of a compound as defined above and in detail below for the preparation of a medicament intended for the prevention and / or treatment of an infection by a mycobacterium in humans or animals.

The invention also relates to a method of manufacturing a medicament intended for preventing and / or treating an infection with a mycobacterium, said method comprising:

1) the supply of a compound as defined above and in detail below, and

2) its introduction into a pharmaceutically acceptable carrier. The subject of the invention is also the use of a compound as defined above and in detail below as a disinfecting and / or decontaminating agent of a material object inert against contaminating agents chosen from mycobacteria. Another subject of the invention relates to a method of therapeutic, curative or preventive treatment of infections with a mycobacterium in a human or animal patient, preferably human, this method comprising:

1) the supply of a compound as defined above and in detail below, optionally in the form of a pharmaceutical composition, and 2) the administration of said compound to the patient. The invention also relates to a compound chosen from the sulphate and / or dichloroacetate salts of the compounds of formula (P) below:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups FL to FL, which are identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group; a C ₆ -C ₁₂ aryl group,

- The FL and R _{9 groups} , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group or FL and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

This set of compounds is noted (PA).

Preferably, the compounds (PA) are chosen from the sulfate and / or dichloroacetate salts of the compounds of formula (I) below:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; -alkyl, Ci-Ci _2; a C ₆ -Ci ₂ aryl group,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

Preferably, in the compounds (PA), the groups R and R ₉ are hydrogen atoms.

More preferably, in the compounds (PA), the groups Ri and R ₂ correspond to the formula - (CH ₂ ) _n -NH ₂ with n an integer ranging from 1 to 40, preferably from 8 to 30, more preferably from 10 at 15. The subject of the invention is also a compound chosen from:

- the compounds of formula (P) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CRsRejm] -,

in which at least one of the groups FL and R ₉ is different from a hydrogen atom.

This set of compound is noted (PB). Preferably, the compounds (PB) are chosen from:

- the compounds of formula (I) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -,

in which at least one of the groups R and R ₉ is different from a hydrogen atom. Preferably, in the compounds (PA) and / or (PB), the groups Ri and R ₂ are identical.

Preferably, in the compounds (PA) and / or (PB), p is equal to 0 in Ri and in R ₂ .

Advantageously, in the compounds (PA) and / or (PB), the groups R ₃ to R <5 are hydrogen atoms.

Preferably, in the compounds (PA) and / or (PB), the groups Ri and R ₂ are chosen, independently, from the groups of formula - (CH ₂ ) _n - NR R ₉ with n an integer ranging from 1 to 40, preferably from 5 to 30, more preferably from 10 to 15.

Advantageously, the compounds (PA) are chosen from the following compounds of formula (2) or (3):

Preferably, the groups R ₈ and R ₉ of the compounds (PB) are chosen independently from the alkyl groups in Ci-Ci _2, preferably in Ci-Cio, more preferentially in Ci-C ₈ , even more preferentially in Ci -C _4, advantageously R ₈ and R ₉ are methyl groups.

More preferably, the groups Ri and R ₂ of the compounds (PB) correspond to the formula - (CH ₂ ) _n -N (R ') ₂ with: - R 'represents a C1-C12 alkyl, preferably C1-C10, more preferably _Cl-C8, more preferably C1-C4, and is preferably a methyl group, and

n an integer ranging from 1 to 40, preferably from 8 to 30, more preferably from 10 to 15.

Advantageously, the compounds (PB) are chosen from the compounds of formula (4) or (5) below:

A subject of the invention is also the compounds (PA) and / or the compounds (PB) for their use as a medicament, preferably for the prevention and / or treatment of bacterial, fungal, viral, parasitic infections or the treatment of cancer in humans or animals, more preferably for the prevention and / or treatment of bacterial infections, even more preferably for the prevention or treatment of Staphylococcus aureus infections.

Preferably, the compounds (PA) and / or the compounds (PB) are used as a medicament in a preoperative preventive or prophylactic treatment aimed at prevent a postoperative bacterial infection in a healthy carrier patient who is going to have surgery.

Advantageously, the compounds (PA) and / or (PB) are administered by local topical application for bacterial cutaneous-mucosal decolonization, preferably for decolonization on the nasal mucosa of Staphylococcus aureus.

The invention also relates to a pharmaceutical composition comprising at least:

a compound chosen from the compounds (PA) and / or (PB) defined above and in detail below, and

- a pharmaceutically acceptable excipient.

Preferably, the pharmaceutically acceptable excipient is chosen from lipophilic excipients, preferably from: petrolatum, lanolin, glycerol esters, macrogols, esters of fatty acids and macrogols.

The invention also relates to the use of a compound chosen from the compounds (PA) and / or (PB) defined above and in detail below for the preparation of a medicament which can be used for the prevention and / or in the treatment of bacterial, fungal, viral, parasitic infections or in the treatment of cancer in humans or animals, more preferably for prevention and / or in the treatment of bacterial infections, even more preferably for prevention or the treatment of a Staphylococcus aureus infection.

The invention also relates to a process for the manufacture of a medicament intended for preventing and / or treating a bacterial, fungal, viral or parasitic infection or for treating cancer in humans or animals, said process comprising:

1) the supply of a compound chosen from the compounds (PA) and / or the compounds (PB) defined above and in detail below, and

2) its introduction into a pharmaceutically acceptable carrier. The subject of the invention is also a disinfecting and / or decontaminating composition comprising at least:

a compound chosen from the compounds (PA) and / or the compounds (PB) defined above and in detail below, and

- a suitable support for an application to an inert material object.

The invention further relates to the use of a compound chosen from the compounds (PA) and / or (PB) defined above and in detail below as a disinfecting and / or decontaminating agent of an inert material object. , preferably surgical equipment.

Preferably, in the context of use as a disinfecting and / or decontaminating agent, said compound is formulated in the form of an aqueous solution.

Finally, the invention relates to a method of therapeutic, curative or preventive treatment, of a human or animal patient, preferably human, this method comprising:

1) the supply of a compound chosen from the compounds (PA) and / or the compounds (PB) defined above and in detail below, optionally in the form of a pharmaceutical composition, and

2) the administration of said compound to the patient.

detailed description

The expression “consists essentially of” followed by one or more characteristics, signifies that may be included in the process or the composition of the invention, in addition to the components or steps explicitly listed, components or steps which do not significantly modify the properties and characteristics of the invention.

The expression "between X and Y" includes the limits, unless explicitly stated otherwise. This expression therefore means that the target interval includes the values X, Y and all the values going from X to Y. Definitions

By "alkyl group" is meant within the meaning of the invention a saturated, linear, branched or cyclic hydrocarbon group.

By "aryl group" is meant within the meaning of the invention a hydrocarbon, mono or bicyclic aromatic system. Among the aryl groups, mention may in particular be made of phenyl or naphthyl groups.

By "heterocyclic group" is meant within the meaning of the invention a mono- or bi-cyclic, saturated, unsaturated or aromatic hydrocarbon group comprising one or more heteroatoms such as O, N or S.

By "water-soluble compound" is meant within the meaning of the invention a compound which at room temperature has a solubility greater than or equal to 0.1% by mass relative to a given volume of water.

The expression "pharmaceutically acceptable" refers, within the meaning of the invention, to compounds, compositions and / or dosage forms which are, within the scope of valid medical judgment, suitable for use in contact with cells humans and animals without toxicity, irritation, undue allergic response and the like, and are proportionate to a reasonable benefit / risk ratio.

By "animal" is preferably meant, within the meaning of the invention, a mammal, preferably chosen from domestic and farm animals, more preferably chosen from cats, dogs and horses.

Compounds

The invention relates to the compounds of formula (P) below and their pharmaceutically acceptable salts,

in which the groups Ri and R ₂ are chosen, independently, from the groups of formula - (CR3R4) _n - [X- (CR5R6) _m ] _P -NR8R ₉ in which:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

- the groups R and R ₉ , identical or different, are chosen from: a hydrogen atom; -alkyl, Ci-Ci _2; aryl C ₆ -C ₂ or R and R ₉ together form a heterocyclic group optionally substituted, comprising 5 to 20 atoms,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

According to a first variant, the compounds according to the invention are chosen from the compounds of formula (P ’) below and their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4, - X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; a C ₁ -C ₁₂ alkyl group; a C ₆ -Ci ₂ aryl group,

- the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ -NHR _S _I0 with s an integer ranging from 1 to 5 and Rio a hydrogen atom, an alkyl group in C -C _l2 aryl or C ₆ -C _2, and

- the groups R and R ₉ , identical or different, are chosen from: a hydrogen atom; a C ₁ -C ₁₂ alkyl group; aryl C ₆ -C ₂ or R and R ₉ together form a heterocyclic group optionally substituted, comprising 5 to 20 atoms,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -. According to a second variant, the compounds according to the invention are chosen from the compounds of formula (P) and their only pharmaceutically acceptable in which the groups Ru and R ₁₂ both represent a methyl group.

Advantageously, the compounds according to the invention are chosen from

- the compounds of formula (I) below,

- their enantiomers, and

- the pharmaceutically acceptable salts of these compounds,

in which the groups Ri and R ₂ are chosen, independently, from the groups of formula - (CR ₃ R ₄ ) _n - [X- (CR ₅ R ₆ ) _m ] _P -NR ₈ R ₉ in which:

- n and m are integers, identical or different, ranging from 1 to 40, - p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

- the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ -NHR _S _I0 with s an integer ranging from 1 to 5 and Rio a hydrogen atom, an alkyl group in C -C _l2 aryl or C ₆ -C _l2, and

- the groups R and R ₉ , identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group; a C ₆ -C ₁₂ aryl group or R and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

- The groups Ru and R ₁₂ , identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

More advantageously, the compounds according to the invention are chosen from:

- the compounds of formula (I), and

- their pharmaceutically acceptable salts.

According to a first variant, the compounds according to the invention are chosen from:

- the compounds of formula (G) below,

- their enantiomers, and

- the pharmaceutically acceptable salts of these compounds,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; -alkyl, Ci-Ci _2; a C ₆ -C ₁₂ aryl group,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X-

(CR ₅ R6) m] -.

More advantageously, the compounds according to the invention are chosen from:

- the compounds of formula (G), and

- their pharmaceutically acceptable salts.

According to a second variant, the compounds according to the invention are chosen from the compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts in which the groups Ru and R ₁₂ are both a methyl group.

According to a first embodiment, the compounds according to the invention are chosen from the sulfate and / or dichloroacetate salts of the compounds of formula (P) defined above.

This set of compounds is designated (PA). Advantageously, according to this first embodiment, the compounds according to the invention are chosen from the sulfate and / or dichloroacetate salts:

- compounds of formula (I) as defined above, and

- their enantiomers.

This set of compounds is designated (IA).

More advantageously, according to this first embodiment, the compounds according to the invention are chosen from the sulfate and / or dichloroacetate salts of the compounds of formula (I) as defined above.

This set of compounds is designated (IA ’).

According to a second embodiment, the compounds according to the invention are chosen from:

the compounds of formula (P) defined above in which at least one of the groups R and R ₉ is different from a hydrogen atom, and

- their pharmaceutically acceptable salts.

This set of compounds is designated (PB).

Advantageously, according to this second embodiment, the compounds according to the invention are chosen from:

the compounds of formula (I) as defined above in which at least one of the groups R and R ₉ is different from a hydrogen atom,

- their enantiomers, and

- the pharmaceutically acceptable salts of these compounds.

This set of compounds is designated (IB).

More advantageously, according to this second embodiment, the compounds according to the invention are chosen from:

the compounds of formula (I) as defined above in which at least one of the groups R and R ₉ is different from a hydrogen atom, and

- their pharmaceutically acceptable salts.

This set of compounds is designated (IB '). The sulfate and / or dichloroacetate salts of the compounds of formula (P) (compounds (PA)), as well as the compounds of formula (P), optionally in the form of pharmaceutically acceptable salts, in which at least one of the groups Rs and R ₉ is different from a hydrogen atom (compounds (PB)), are new and constitute in themselves an object of the invention, as well as the compositions comprising them, in particular the pharmaceutical compositions or the compositions disinfectants including them.

The technical characteristics presented below constitute variants and preferred embodiments of the compounds of formula (P) and of formula (I) defined above. They constitute, in particular, variants and preferred embodiments of the compounds (PA), (IA), (IA ’), (PB), (IB) and (IB’) defined above. They also constitute preferred variants and embodiments of the compositions, methods and uses which will be described below.

According to a preferred embodiment, the groups Ri and R ₂ are identical.

When at least one of the groups FL to R ₆ is chosen from C ₁ -C ₁₂ alkyl groups, preferably, the alkyl group or groups are linear or branched, even more preferably linear.

When at least one of groups R ₃ to R ₆ is selected from alkyl C ₁ -C _12, preferably, the alkyl groups C ₁ -C ₁₂ are selected from alkyl C ₁ - C ₁₀ , more preferably in Ci-C ₆ , and even more preferably in C ₁ -C ₄ .

In particular, when at least one of the groups R ₃ to R < ₅ is chosen from C ₁ -C ₄ alkyl groups, it is preferably chosen from methyl, ethyl, propyl, n-butyl and isobutyl.

When at least one of the groups R ₃ to R ₆ is chosen from C ₆ -Ci ₂ aryl groups, preferably, the C ₆ -Ci ₂ aryl group or groups are phenyl groups.

The groups R ₃ to R < ₅ are preferably chosen independently from a hydrogen atom and a C ₁ -C ₁₂ alkyl group. Advantageously, at least one of the groups R ₃ to R ₆ is a hydrogen atom.

Advantageously, the groups R ₃ and R4 are identical, even more preferably R ₃ and R4 are the hydrogen atom.

Advantageously, the groups R5 and R ₆ are identical, even more preferably R5 and R _e are the hydrogen atom.

Advantageously also, the groups R ₃ to R ₆ are all identical, even more preferably the groups R ₃ to R _e all represent a hydrogen atom.

According to a first embodiment, p is strictly greater than 0 in at least one of the groups Ri and R ₂ .

Advantageously, according to this embodiment, p is chosen from 1, 2 and 3.

Preferably, according to this embodiment, Ri and R ₂ are identical.

Preferably, according to this embodiment, n is an integer ranging from 1 to 20, more preferably from 1 to 10, even more preferably from 1 to 5.

Preferably, m is an integer ranging from 1 to 20, more preferably from 1 to 10, even more preferably from 1 to 5, m being chosen independently for each unit - [X- (CR5Ré) _m ] - ·

Preferably, m is the same for all units - [X- (CR5R6) _m ] - ·

Preferably, X is the same for all units - [X- (CR5R6) _m ] - ·

Preferably, the groups R5 and R ₆ are the same for all the units -

[X- (CR ₅ R6) m] -.

Advantageously, R 5 = R ₆ = H.

When p> 0, according to a first variant, X represents an oxygen atom.

Preferably, according to this first variant, at least one of the groups - NHRi and --NHR ₂ is chosen from:

When p> 0, according to a second variant, X represents a group of formula -NR ₇ -, R ₇ being as defined above. Preferably, according to this second variant, R ₇ represents a hydrogen atom, a C ₁ -C ₃ alkyl or a group - (CH ₂ ) _S NHR _I0 , with s an integer ranging from 2 to 4 and Rio an atom of hydrogen, a C ₁ -C ₁₂ alkyl group or a C ₆ -C ₁₂ aryl group.

Even more preferably, according to this second variant, R ₇ represents a hydrogen atom, a methyl group or a - (CH ₂ ) _S NH _{2 group} , with s = 2 or 3.

Preferably, according to this second variant, at least one of the groups - NHRi and --NHR ₂ is chosen from:

According to a preferred embodiment, p is equal to 0 in at least one of Ri and

R ₂ .

Advantageously, p is equal to 0 in Ri and in R ₂ .

When p = 0 in at least one of the groups Ri and R _2. the latter corresponds to the formula:

- (CR ₃ R ₄ ) _n -NR ₈ R ₉

n, R ₃ , R ₄ , R ₈ and R ₉ being as defined above.

Preferably, according to this embodiment, Ri and R ₂ are identical and correspond to the formula - (CR ₃ R ₄ ) _n -NR ₈ R9.

Preferably, according to this embodiment, n is an integer ranging from 5 to 30, more preferably from 8 to 20, even more preferably from 10 to 15. Preferably, according to this embodiment, R ₃ and R ₄ represent the hydrogen atom.

In the compounds of the invention, the groups R and R ₉ , which may be identical or different, are chosen from: a hydrogen atom; alkyl in Ci -C _2; a C ₆ -C ₁₂ aryl group or R and R ₉ together form a heterocyclic group comprising from 5 to 7 atoms, said heterocycle group, optionally substituted, comprising from 5 to 20 atoms.

When at least one of the groups R and R ₉ is chosen from C 1 -C ₂ alkyl groups, preferably, the alkyl group or groups are linear or branched, even more preferably linear.

When at least one of the groups R and R ₉ is chosen from C 1 -C ₂ alkyl groups, preferably, the group or C 1 -C ₂ alkyl groups are chosen from C ₁ -C 10 alkyl groups, more preferably in Ci-C ₆ , and even more preferably in Ci-C ₄ .

In particular, when at least one of the groups R and R ₉ is chosen from C ₁ -C ₄ alkyl groups, it is preferably chosen from the methyl, ethyl, propyl, n-butyl and isobutyl groups.

When at least one of the groups R to R ₉ is selected from aryl C ₆ -C _2, preferably, the aryl groups are C ₆ -Ci2 phenyl groups.

When the groups R and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms, preferably, the heterocyclic group consists of carbon, nitrogen, oxygen and hydrogen atoms, more preferably carbon, nitrogen and hydrogen atoms.

Preferably, the heterocyclic group consists of a heterocycle comprising from 5 to 7 members (ring atoms), said heterocycle being optionally substituted by a group - (CH ₂ ) _q -NH ₂ , with q an integer ranging from 1 to 5.

Advantageously, according to this variant, the group -NR _¾ R ₉ is chosen from:

More advantageously, according to this variant, at least one of the NHRi and -NHR _{2 groups} is chosen from:

Advantageously, the groups R and R ₉ are chosen, independently, from a hydrogen atom

According to a preferred embodiment, at least one of the groups Ri and R ₂ corresponds to the formula - (CH ₂ ) _n -NRsR9 in which:

- n is an integer ranging from 1 to 40, preferably from 8 to 30, more preferably from 10 to 20, even more preferably from 10 to 15

- R and R ₉ are chosen, independently, from a hydrogen atom and a Ci-Ci ₂ alkyl group, preferably from a hydrogen atom or a C1-C ₄ alkyl group, even better from a hydrogen atom and a methyl group. Advantageously, according to this preferred embodiment, the groups Ri and R ₂ are identical.

Advantageously, the groups Ru and R _{i 2} are identical.

According to a first variant, at least one of the groups Ru and R ₁₂ is a hydrogen atom.

Preferably, according to this variant, the Ru and R _{12 groups} both represent a hydrogen atom.

According to a second variant, at least one of the Ru and R _{i 2 groups} is chosen from Ci-Ci ₂ alkyl groups.

Preferably, according to this second variant at least one of Ru and _I2 R groups is selected from alkyl Cl-C _6, more preferably from alkyl C ₁ -C _3, more preferably it is of a methyl group.

Preferably, according to this second variant, the Ru _i and R ₂ groups are both an alkyl group Ci-Ci _2, most preferably Ru _I2 and R both represent methyl.

According to a particular embodiment, the compounds according to the invention are in the form of pharmaceutically acceptable salts.

By “pharmaceutically acceptable salts” is meant within the meaning of the invention addition salts of inorganic or organic acids, pharmaceutically acceptable of the compounds of formula (P) and / or (I) defined above, in particular chosen from the compounds (PA), (IA), (IA '), (PB), (IB) and / or (IB'). These salts include in particular acid addition salts, that is to say salts of organic or inorganic acid of a compound comprising a basic function such as an amino function. These salts can be prepared in situ during the final isolation and / or purification of the compounds. In particular, the acid addition salts can be prepared by reacting the purified compound separately with an organic or inorganic acid and isolating the salt thus formed. Examples of acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate salts. tosylate, citrate, maleate, fumarate, succinate, tartrate, iodate, in particular obtained by reaction with methyl iodate, naphthylate, mesylate, glucoheptanate, lactobionate, sulfamates, malonates, salicylates, propionates, methylene -bis-hydroxynaphtoates, especially methylene- bis- (2-hydro-3naphthoate), gentisic acid, isethionates, di-p- toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p- toluenesulfonates, cyclohexyl sulfamates and quinatelaurylsulfonates, and the like (see, for example, SM Berge Pharmaceuticals and al. "J. Pharm. Sci, 66, p.1 - 19 (1977)). Preferably, according to this particular embodiment, the pharmaceutically acceptable salts are chosen from water-soluble salts.

More preferably, according to this particular embodiment, the compounds according to the invention are in the form of hydrochloride, hydrobromide, triflate, phosphate, lactate, succinate, sulfate and / or dichloroacetate salts, preferably in the form of sulfate salts and / or dichloroacetate.

Among the compounds according to the invention, mention may in particular be made of the compound of formula (1) below:

According to a first advantageous embodiment, the compounds according to the invention are chosen from the sulfate and / or dichloroacetate salts of the compounds of formula (P) defined above (compounds (PA)), preferably from the compounds ( IA) defined above, even more preferably from the compounds (IA ′) defined above.

Preferably, according to this embodiment, the groups R and R ₉ are hydrogen atoms. Preferably, according to this embodiment, the compound according to the invention comprises at least one quaternized nitrogen atom, more preferably at least two quaternized nitrogen atoms.

Advantageously, still according to this embodiment, all of the nitrogen atoms present in the compound according to the invention are quaternized.

Preferably, according to this embodiment, the groups Ri and R ₂ are identical and represent a group of formula - (CH ₂ ) _n -NH ₂ , with n an integer ranging from 1 to 40, preferably from 5 to 30, more preferably from 8 to 20, even more preferably from 10 to 15.

Advantageously, according to this embodiment, n = 12.

More advantageously, according to this embodiment, the compounds according to the invention are chosen from the compounds of formulas (2) and (3) below:

According to a second advantageous embodiment, the compounds according to the invention are chosen from the compounds of formula (P) defined above, optionally in the form of pharmaceutically acceptable salts, in which at least one of the groups R and R ₉ is different from a hydrogen atom (compounds (PB)), preferably from the compounds (IB) defined above, even more preferably from the compounds (IB ') defined above. Preferably, according to this second embodiment, the groups Ri and R ₂ correspond to the formula - (CH ₂ ) _n -NR8R9 in which:

n is an integer ranging from 1 to 40, preferably from 5 to 30, more preferably from 8 to 20, even more preferably from 10 to 15, and

- R and R ₉ are chosen, independently, from a hydrogen atom and a Ci-Ci ₂ alkyl group, it being understood that at least one of the groups R and R ₉ is different from an atom of hydrogen.

In a first variant, one of the groups R and R ₉ is a hydrogen atom and the other is an alkyl group Ci-Ci _2.

According to a second preferred variant, the groups R and R ₉ are chosen, independently, from the Ci-Ci ₂ alkyl groups.

Preferably, according to this second variant, the groups R and R ₉ are identical.

Advantageously, according to this embodiment, the groups Ri and R ₂ are identical and represent a group of formula - (CH ₂ ) _n -NR ₈ R ₉ in which:

- Rs and R ₉ are identical and represent an alkyl group in Ci-Ci ₂ , preferably in Ci-Cio, more preferentially in Ci-C ₆ , and even more preferentially in Ci-C ₄ .

Preferably, Rs and R ₉ are identical and are chosen from methyl, ethyl, propyl, n-butyl and iso-butyl groups, even more preferably is a methyl group.

Advantageously, according to this second embodiment, n = 12.

Even more advantageously, according to this embodiment, the compound according to the invention is chosen from the compounds of formula (4) or (5) below:

Pharmaceutical composition

The compounds according to the invention can be incorporated into a pharmaceutically acceptable excipient to form a pharmaceutical or veterinary composition.

A pharmaceutical or veterinary composition according to the invention comprises at least:

- a compound according to the invention, and

- a pharmaceutically acceptable excipient.

According to a particular embodiment, the pharmaceutical or veterinary compositions according to the invention can comprise an antibiotic compound distinct from the compounds of the invention. In particular, they may comprise a compound chosen from the family of beta-lactam antibiotics (penicillins / cephalosporins), aminoglycosides, macro lides, polypeptides, sulfonamides, quinolones, nitro-imidazoles and their derivatives, nitrofuran derivatives, derivatives benzyl-pyrimidine ring, tetracyclines or phenolic and their derivatives.

The pharmaceutical or veterinary compositions according to the invention can also comprise a second compound which exhibits antiparasitic activity, in particular an antimalarial.

The pharmaceutical or veterinary compositions according to the invention may be in solid or liquid forms, intended for example for administration by the parenteral (intravenous, intramuscular, subcutaneous), oral or topical route.

They will therefore be presented in the form of solutions or injectable suspensions, in particular ingestible or drinkable, in the form of naked or coated tablets, dragees, capsules, capsules, pills, cachets, powders, granules, suppositories, rectal capsules or aerosol. When the pharmaceutical or veterinary compositions according to the invention are in the form of solutions or injectable suspensions, they can then be packaged in single-dose or multi-dose vials.

Preferably, the pharmaceutical or veterinary compositions according to the invention are in the form of ingestible or drinkable solutes or suspensions, bare or coated tablets, capsules or even aerosol.

Advantageously, the pharmaceutical or veterinary composition according to the invention also comprises one or more additional ingredients well known to those skilled in the art such as, in particular, binding agents, granulating agents, lubricants, dyes, fillers, emulsifiers, minerals, film-coating agents, salts, stabilizers, buffers or vitamins. Stabilizers include substances which tend to increase the shelf life of the composition such as preservatives, emulsifiers, thickeners, packaging gases, gelling agents, humectants, sequestrants, synergists or stabilizers.

For parenteral use, water, aqueous solutions, physiological saline, isotonic solutions are the most conveniently used vehicles. For percutaneous use, in particular on the skin, mucous membranes or the hair, in particular for pouring solutions of the “pour-on” or “spot-on” type in veterinary medicine, the usual excipients are aqueous, alcoholic solvents , polar or not, which promote the transcutaneous passage, such as water, benzyl alcohol, vegetable and mineral oils, resuspension agents, antioxidants, surfactants, in particular a mixture consisting of benzyl alcohol and / or labrasol and / or propylene glycol laurate, as a penetrating agent can be used.

The dosage can vary within wide limits (0.05 mg to 1000 mg) depending on the therapeutic indication and the route of administration, as well as the subject's age and weight.

According to a particular embodiment, the pharmaceutically acceptable excipient is chosen from lipophilic excipients.

The lipophilic excipient is preferably chosen from petrolatum, lanolin, glycerol esters, macrogols, esters of fatty acids and macrogols and their mixtures. Preferably, according to this embodiment, the pharmaceutical or veterinary composition according to the invention is in the form of a lotion, a cream, an ointment or even an ointment.

Such a pharmaceutical composition is particularly suitable for use topically locally for bacterial cutaneous-mucosal decolonization, in particular of the nasal mucosa.

A pharmaceutical or veterinary composition according to the invention preferably comprises from 0.01 to 10% by mass, preferably from 0.5 to 5% by mass, and more preferably from 1 to 5% by mass of at least a compound according to the invention, relative to the total mass of the pharmaceutical or veterinary composition.

Therapeutic applications

All the compounds of the invention are of interest for the prevention and / or treatment of an infection with a mycobacterium.

A subject of the invention is therefore the compounds according to the invention, optionally in the form of a pharmaceutical or veterinary composition as defined above, for their use as a medicament in the treatment and / or prevention of infections by a mycobacterium in humans or animals, preferably humans.

The subject of the invention is also a method of therapeutic, curative or preventive treatment of infections with a mycobacterium in a human or animal patient, preferably human, this method comprising:

1) the supply of a compound according to the invention, optionally in the form of a pharmaceutical composition as defined above, and

2) the administration of said compound to the patient according to at least one of the routes of administration defined above.

The invention also relates to the use of a compound according to the invention for the preparation of a medicament intended for the prevention and / or treatment of an infection by a mycobacterium in humans or animals, preferably in humans.

The subject of the invention is also a method for preparing a medicament intended for preventing and / or treating an infection with a mycobacterium, said method comprising: 1) the supply of a compound according to the invention, and

2) the introduction of said compound into a pharmaceutically acceptable carrier.

The mycobacterium responsible for the infection is preferably chosen from

Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium abscessus, Mycobacterium massiliense, Mycobacterium chelonae, Mycobacterium immunogenum, Mycobacterium bolletii, Mycobacterium avium avium, Mycobacterium avium intracelluliumcumiobium aciumobium mycobacterium avium homcobacterium avium homicobium, tuberculosis.

The invention also relates to the sulfate and / or dichloroacetate salts of the compounds of formula (P) (compounds (PA)) and / or the compounds of formula (P), optionally in the form of pharmaceutically acceptable salts, in which l at least one of the groups R and R ₉ is different from a hydrogen atom (compounds (PB)), optionally in the form of a pharmaceutical or veterinary composition as defined above, for their use as a medicament.

The invention relates more particularly to the compounds (PA) and / or the compounds (PB) as defined above for their use as a medicament for the prevention and / or treatment of bacterial, fungal, viral, parasitic infections or the treatment of cancer in humans and / or animals.

The compounds (PA) and / or the compounds (PB) according to the invention are particularly effective for the prevention and / or treatment of bacterial infections, in particular by Staphylococcus aureus.

The subject of the invention is also a method of therapeutic, curative or preventive treatment, of a human or animal patient, preferably human, this method comprising:

1) the supply of a compound chosen from compounds (PA) and compounds (PB), optionally in the form of a pharmaceutical composition as defined above, and

2) the administration of said compound to the patient according to at least one of the routes of administration defined above. The compounds (PA) and / or the compounds (PB) according to the invention are particularly suitable for local topical application for bacterial cutaneous-mucosal decolonization.

By “local topical application” is meant within the meaning of the invention a procedure consisting in applying the compound to the skin or to a mucous membrane, said compound being formulated as a lotion, cream, ointment, paste, ointment or aerosol, in the case nasal or oral application.

The compounds (PA) and / or the compounds (PB) according to the invention are preferably applied to the nasal mucosa. These compounds can however be considered for application to different places on the skin, in particular at the level of the skin folds and, more particularly, at the level of the armpits.

According to a particular embodiment, the compounds (PA) and / or the compounds (PB) according to the invention are used in a preoperative preventive or prophylactic treatment aimed at preventing a postoperative bacterial infection in a healthy carrier patient who will be subjected to a surgery.

Preferably, according to this particular embodiment, the compounds (PA) and / or the compounds (PB) according to the invention are used to prevent infection by Staphylococcus aureus.

The invention also relates to the use of compounds (PA) and / or compounds (PB) according to the invention for the preparation of a medicament.

The invention relates more particularly to the use of compounds (PA) and / or of compounds (PB) for the preparation of a medicament which can be used for the prevention and / or in the treatment of bacterial, fungal, viral, parasitic or in the treatment of cancer in humans or animals, preferably for the prevention or in the treatment of bacterial infections.

The invention also relates to a process for manufacturing a medicament, said process comprising:

1) the supply of at least one compound chosen from compounds (PA) and compounds (PB), and

The medicament is preferably intended to prevent and / or treat a bacterial, fungal, viral or parasitic infection or to treat cancer in humans or the animal, more preferably intended for preventing and / or treating a bacterial infection, in particular by Staphylococcus aureus.

Use as disinfectant and / or decontaminant

The compounds according to the invention are also effective as disinfectants and / or decontaminants against contaminating agents chosen from among mycobacteria.

The compounds according to the invention are particularly effective against Mycobacterium tuberculosis, Mycobacterium africanum and Mycobacterium xenopi.

By "disinfecting and / or decontaminating agent" is meant within the meaning of the invention a compound capable of killing and / or inactivating and / or stopping the development of microorganisms such as bacteria, viruses and protozoa .

Unlike an antiseptic agent intended to be applied to the human or animal body or an antibiotic agent intended to be administered inside the human or animal body, a disinfecting and / or decontaminating agent has the objective of disinfecting and / or decontaminate an inert material object.

There are European standards NF EN 1040 (for bacteria) and EN 1275 (for yeasts) to qualify a chemical compound as a chemical disinfecting agent for use in the pharmaceutical, medical, dental, veterinary, agro-food, industrial, and for domestic or collective use. According to the standards in force, a disinfecting agent must kill 99.999% of the targeted germs, i.e. a reduction of 5 log starting from an inoculum of 10 ⁸ cfu / ml gram + and gram bacteria - S. aureus and P. aeruginosa and 99, 99% for mushrooms, ie a reduction of 4 log starting from an inoculum of 10 ⁸ cfu / ml mushrooms (A niger and C. albicans).

The sulphate and / or dichloroacetate salts of the compounds of formula (P) (compounds (PA)) and / or the compounds of formula (P), optionally in the form of pharmaceutically acceptable salts, in which at least one of the groups R and R ₉ is different from a hydrogen atom (compounds (PB)) are also effective as disinfectants and / or decontaminants against contaminating agents chosen from bacteria, fungi, viruses and parasites. The compounds (PA) and / or the compounds (PB) according to the invention are, in particular, effective as disinfecting agents and / or decontaminants against bacteria, in particular against Staphylococcus aureus.

The compounds according to the invention are in particular suitable for the disinfection and / or decontamination of objects used in particular in the food, housing, transport sectors, as well as the medical sectors, in particular pharmaceutical or diagnostic, dental, surgical, to guarantee the sterility of the instruments used.

We can cite more particularly:

- utensils for food in communities and especially for feeding infants such as bottles, teats, pacifiers, ...

- surgical instruments such as scalpels, surgical prostheses, pins, ...

- medical devices such as eye contact lenses, and endoscopic devices such as probes, endoscopes, respiratory masks, ...

- devices for administering pharmaceutical compositions such as nebulizers.

These are more particularly objects, in particular rigid, made of plastic polymer material; inorganic or mineral material; metallic material, especially steel; or even composite material.

Mention may also be made of the field of transport, in particular stretchers and interior trim of vehicles, in particular of ambulances, or else the field of housing or transport for domestic or collective use, in particular residential objects such as furniture and immovable objects such as floors, walls, water pipes, seats, door handles, stretchers.

Disinfecting and / or decontaminating composition

The compounds according to the invention can for example be used in the form of a disinfecting and / or decontaminating composition.

A disinfecting and / or decontaminating composition comprises at least:

- a compound according to the invention, and

- a support adapted to an application to an inert material object. The disinfecting and / or decontaminating composition can optionally comprise one or more suitable excipients. Such excipients are well known to those skilled in the art who will know how to choose and adapt them according to the intended application.

According to a first variant, the disinfecting and / or decontaminating composition is in the form of a water-soluble composition, preferably in the form of a tablet soluble in water.

Such a composition is advantageous in that it makes it possible to reduce the volume of product to be transported and / or stored.

The water-soluble composition, in particular the tablet, then consists of a portion suitable for being dissolved or dissolved in a given volume of solvent, in particular water, in order to obtain a disinfecting and / or decontaminating composition in the form of a solution. or a dispersion.

According to a second variant, the disinfecting and / or decontaminating composition is in the form of a solution and / or of a dispersion in a liquid solvent.

Preferably, the liquid solvent is chosen from volatile liquid solvents, more preferably from water and alcohols.

More preferably, the liquid solvent is water.

The content of compound according to the invention in the disinfecting and / or decontaminating composition is preferably at least 3 mmol.L ¹ (mM), more preferably from 3 to 250 mM.

According to a particular embodiment, the disinfecting and / or decontaminating composition is contained in a substrate such as for example a wipe impregnated with a solution or dispersion as defined above.

The different embodiments, variants, preferences and advantages described above for each of the objects of the invention apply to all of the objects of the invention and can be taken separately or in combination.

The invention is illustrated by the following examples given without limitation. Experimental part :

1. Synthesis of the compounds

Compounds (1), (2), (3), (4) and (5) were synthesized according to the following protocols.

Compound synthesis (1)

Compound (1), represented below, was synthesized according to the protocol described in Djouhri-Bouktab L, Vidal N, Rolain JM, Brunel JM. Synthesis of new 3,20- bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. J Med Chem. 2011 Oct; 54 (20): 74l7-2l [8]

Compound synthesis (2)

Compound (2), represented below, was synthesized from compound (1) obtained above according to the following protocol:

100 mg (0.12 mM) of compound (1) are dissolved in 1 mL of pure H ₂ S0 ₄ sulfuric acid (CAS No: 7664-93-9). The solution obtained is then placed in an ultrasonic bath (Branson Ultrasonic) maintained at a temperature of 35 ° C for 3 hours. To the mixture cooled to a temperature of 5 ° C. are added 2 ml of ethanol (CAS N °: 64-17-5). The solution obtained is then stored overnight in the freezer at a temperature of -18 ° C. The solution is then filtered and the supernatant solid isolated. At 2 ml of ethanol are then added to the supernatant. The solution obtained is then placed in an ultrasonic bath maintained at a temperature of 35 ° C for 3 hours, before being cooled to a temperature of -20 ° C overnight. The solid fraction obtained is finally filtered and placed in a desiccator under vacuum in the presence of magnesium sulfate MgS0 ₄ (CAS No: 7487-88-9). 30 mg of compound (2) are finally obtained.

Compound synthesis (3)

Compound (3), represented below, was synthesized from compound (1) obtained above according to the following protocol:

100 mg (0.12 mM) of compound (1) are dissolved in a minimum volume of ethanol (approximately 3 mL). To this solution are added 12 molar equivalents of dichloroacetic acid. The mixture obtained is then placed in an ultrasonic bath maintained at a temperature of 50 ° C for 4 hours. The solvent is then evaporated using a vacuum pump to collect a solid residue.

The solid residue obtained is then dissolved in 2 ml of ethanol. 2 ml of ethyl ether (CAS N °: 60-29-7) are then added to the solution obtained which is then placed overnight in the freezer at a temperature of -18 ° C. The solid fraction obtained is then filtered and placed in a desiccator under vacuum in the presence of magnesium sulfate MgS0 ₄ . This series of operations is repeated once.

75 mg of compound (3) are finally obtained.

Compound synthesis (4)

Compound (4), represented below, was synthesized from compound (1) obtained above according to the following protocol:

The compound (1) is reacted with hydrochloric acid according to a molar ratio of compound (1): hydrochloric acid equal to 1: 4. The hydrochloride of the compound (1) thus obtained (75 mg, 9.10-5 mol) is dissolved in water (5 mL). Potassium carbonate (200 mg, 1.4 mmol) is then added to the aqueous composition obtained which is left to react for 30 minutes. The product obtained is then extracted with a dichloromethane / ethyl acetate mixture at a volume ratio 2: 8. The organic phase collected is then dried with anhydrous sodium sulfate Na ₂ S0 ₄ , then filtered and finally concentrated under reduced pressure. The solid obtained (9.10-5 mol) is then dissolved in 200 μL of formic acid (88% in aqueous solution) and 200 μL of formaldehyde (in aqueous solution) before being heated to 80 ° C. and placed under stirring for 24h. After cooling to room temperature, the reaction mixture is diluted with water and then treated with potassium carbonate in order to make the medium basic (pH 10). The product obtained is then extracted with a dichloromethane / ethyl acetate mixture at a volume ratio 2: 8. The resulting organic phase is then washed with brine and then dried with anhydrous sodium sulfate Na ₂ S0 ₄ before being concentrated under reduced pressure. The crude product is then purified by chromatography on a silica column (eluent: dichloromethane / methanol / ammonia according to a volume ratio 7: 3: l). The product (4) is obtained with a yield of 58%.

Synthesis of the compound (5)

Compound (5), represented below, was synthesized from compound (1) obtained above according to the following protocol:

The compound (1) is reacted with hydrochloric acid according to a molar ratio of compound (1): hydrochloric acid equal to 1: 4. The hydrochloride of the compound (1) thus obtained (75 mg, 9.10 ⁵ mol) is dissolved in water (5 mL). Potassium carbonate (200 mg, 1.4 mmol) is then added to the aqueous composition obtained which is left to react for 30 minutes. The product obtained is then extracted with a dichloromethane / ethyl acetate mixture at a volume ratio 2: 8. The organic phase collected is then dried with anhydrous sodium sulfate Na ₂ S0 ₄ , then filtered and finally concentrated under reduced pressure. The solid obtained (9.10 ⁵ mol) is then dissolved in 2 ml of formic acid (88% in aqueous solution,> 400 equivalents) and 2.5 ml of formaldehyde (in aqueous solution,> 400 equivalents) before being heated to 80 ° C and stirred for 24 h. After cooling to room temperature, the reaction mixture is diluted with water and then treated with potassium carbonate in order to make the medium basic (pH 10). The product obtained is then extracted with a dichloromethane / ethyl acetate mixture at a volume ratio 2: 8. The resulting organic phase is then washed with brine and then dried with anhydrous sodium sulfate Na ₂ S0 ₄ before being concentrated under reduced pressure. The crude product is then purified by chromatography on a silica column (eluent: ethyl acetate then methanol then dichloromethane / methanol / ammonia according to a volume ratio 7: 3: l). The product (5) is obtained with a yield of 75%.

1H NMR (250MHz): 0.72-0.98 (m, 12H), 1.02-1.28 (m, 10H), 1.29-1.98 (m, 29H),

1.98-2.18 (m, 3H), 2.37-2.46 (m, 8H), 2.12-2.34 (m, 2H), 2.69-2.89 (m, 12H), 2.91- 3.51 (m, 10H), 3.59-3.64 (m , 1H), 3.95-4.10 (m, 1H), 5.31-5.38 (m, 1H). 2. Evaluation of anti-tuberculosis activity

The anti-tuberculosis activity of squalamine, rifampicin and compounds (1), (2), (3) and (4) synthesized above was evaluated. Rifampicin is an antibiotic well known for its anti-tuberculosis activity. Here it is a comparison.

Squalamine is studied as a comparison.

The compounds (1), (2), (3) and (4) are according to the invention.

Material and methods :

The anti-tuberculosis activity of the compounds is evaluated by determining the minimum inhibitory concentration (MIC) of each of the compounds according to the micro-dilution plate method.

Several suspensions of Mycobacterium tuberculosis H37Rv are first prepared by incubation of the colonies, at 37 ° C and with constant stirring at 300 rpm for 7 days, in a mixture comprising:

- 100 mL of liquid Middlebrook 7H9 medium,

- 0.5 ml of Tween 80,

- 0.5 ml of Glycerol, and

- 100 ml of an OADC mixture (8.5 g / L of sodium chloride, 20.0 g / L of dextrose, 50.0 g / L of bovine albumin, 0.03 g / L of catalase and 0 , 6 mL / L of oleic acid) commercially available under the reference BBL ™ Middlebrook OADC Enrichment.

On the day of the experiment, the turbidity of the suspension is adjusted to 1 McLarland by the introduction of 7H9 medium.

For each of the compounds to be studied, 8 solutions of decreasing concentration are prepared by successive dilutions of a basic solution in the 7H9 medium by means of a 96-well plate organized in the form of 12 columns of 8 wells each. For the sake of simplification, each column is associated with a specific compound and each row with a precise concentration. For each column, the first well thus comprises the most concentrated solution and the last well the least concentrated solution. The solutions thus prepared have respectively a concentration equal to 100 - 50 - 25 - 12.5 - 6.25 - 3.125 - 1.56 - 0.78 pg / mL.

10 μL of the suspension of Mycobacterium tuberculosis calibrated at 1 McLarland are then added to 90 μL of each of the solutions prepared above. Volume final of each well is then 100 μL and the bacterial concentration of approximately 10 ⁵ cfu / ml in each well.

Negative control wells (culture medium only) and growth control wells (inoculum + culture medium) are also integrated on the 96-well plate.

The 96-well plate is then incubated at 37 ° C.

After 5 days of incubation, the minimum inhibitory concentration (MIC) of each of the compounds is evaluated by spectrophotometric analysis following the addition of iodonitrotetrazolium in each of the wells. Iodonitrotetrazolium is a vital dye responsible for a purplish coloring of the medium in the presence of living bacteria.

The experiment is repeated so as to obtain 3 series of results.

On each plate, each compound is represented twice (2 different columns).

The measurement of the MIC of each of the compounds was thus carried out 6 times in total. Results:

The results obtained are given in Table 1 below.

Table 1: Antibacterial activity against Mycobacterium tuberculosis

Rifampicin, used as a control, is very active against Mycobacterium tuberculosis and has an MIC of less than 0.78 pg / mL.

Squalamine has an MIC between 50 and 100 pg / mL. Squalamine is therefore not active against Mycobacterium tuberculosis.

The compounds (1), (2), (3) and (4) according to the invention have an MIC of between 3.125 and 6.25 pg / ml.

Compounds (1), (2), (3) and (4) are therefore active towards Mycobacterium tuberculosis.

3. Evaluation of the antibacterial activity against Staphylococcus aureus a) In vitro evaluation of the inhibitory activity of compounds (1), (2), (3), (4) and (5) against Staphylococcus aureus The antibacterial activity against Staphylococcus aureus of squalamine, muporicin, vancomycin and compounds (1), (2), (3), (4) and (5) synthesized above was evaluated.

Mupirocin and vancomycin are antibiotics known for their antibacterial activity against Staphylococcus aureus. They constitute here comparisons.

Squalamine is studied as a comparison.

The compounds (1), (2), (3), (4) and (5) are according to the invention.

Material and methods :

The antibacterial activity of the compounds against Staphylococcus aureus is evaluated by determining the minimum inhibitory concentration (MIC) of each of the compounds according to the microdilution method in a plate detailed below.

The protocol for preparing the plates is similar to that described above in the context of the evaluation of the anti-tuberculosis activity of the compounds with the exception of:

- the Middlebrook 7H9 culture medium is replaced by Mueller Hinton II Broth medium, adjusted as a function of the calcium and magnesium ions. This product is commercially available from Becton Dickinson.

- the experiment is carried out 3 times from 3 distinct bacterial strains: o S. aureus ATCC 25923 (sensitive to methicillin), noted below MSSA,

o S. aureus CF Marseille CSUR P 102 (methicillin resistant), noted below MRSA, and

o S. aureus CSUR P 1946 (resistant to methicillin and mupirocin), noted below Mup-R.

- for each of the bacterial cultures, the inoculum is prepared as follows: the bacterial suspension is adjusted to 0.5 McFarland and then diluted to 1:20. 10 pF of this suspension are then added to each of the wells to obtain a total volume of 100 pF for each of the wells (90 pF of antibacterial solution + 10 pF of bacterial suspension). The bacterial concentration of each well is equal to 5.10 ⁵ cfu / mF.

- the incubation time is reduced to 24 hours.

Results: The results obtained are given in the following table 2.

Table 2: Antibacterial activity in vitro against Staphylococcus aureus

Vancomycin, used as a control, is very active against all Staphylococcus aureus strains and has an MIC of between 0.78 and 1.56 pg / mL on all the strains tested.

Muporicin, used as a control, is very active against the MSSA and MRSA strains and has, vis-à-vis these two strains, an MIC equal to 0.39 pg / ml. The tests carried out also confirm that the Mup-R strain is very resistant to muporicin (MIC> 100 pg / mL).

The squalamine and the compounds (1), (2), (3), (4) and (5) according to the invention have an MIC equal to 3.125 pg / ml for all the strains tested.

Compounds (1), (2), (3), (4) and (5), as well as squalamine, are therefore active against all of the Staphylococcus aureus strains studied. b) In vivo evaluation of the inhibitory activity of compound (5) against Staphylococcus aureus

The efficacy of a petrolatum-based ointment comprising 1% by mass of the compound (5) prepared above is evaluated in a cutaneous colonization model of Staphylococcus aureus resistant to mupirocin (CSUR P 1946). Protocol:

Mice are shaved at their dorsal region to obtain a hairless area. 10 μL of a bacterial suspension calibrated at 10 ⁷ cfu / ml is then deposited on the shaved skin of the mice.

lh after the deposition, the mice are divided into 2 groups:

the mice of the first group receive a single application of the ointment prepared above, and

- the mice of the second group receive a single application of petroleum jelly (control group).

The bacterial count (= the concentration of bacteria on the surface of the mouse skin) is determined before the application of the ointment (t ₀ ) and 30 minutes after the application of the ointment (t ₃₀ ) by skin swabbing and placing in culture on Chapman agar.

The reduction in the bacterial count is finally calculated by making the difference between the bacterial count measured at t ₃₀ and the bacterial count measured at to.

Results:

The results obtained are presented in Table 3 below.

Table 3: Antibacterial activity in vivo against Staphylococcus aureus of compound (4b)

* comparison

A reduction in the bacterial count equal to 0.7 log cfu / ml is observed in the group having received a dose of petrolatum (control sample).

A reduction in the bacterial count equal to 1.8 log cfu / ml is observed in the group having received a dose of the ointment based on the compound (5).

A significant difference of 1 log is thus noted between the group of mice having received the application of the ointment based on compound (5) and the control group. These results demonstrate that a single application of compound (5) makes it possible to reduce the bacterial count of Staphylococcus aureus with a significant difference of 1 log compared to the control group and this from the first 30 minutes following the application of the ointment. This rapidity of action in a single dose constitutes a superiority compared to mupirocin which is administered at the rate of 2 applications per day for 5 days for the nasal decolonization of Staphylococcus aureus in the clinic.

These results also demonstrate the superiority of the compound (5) compared to the prior art and more specifically compared to the ASD-2 compound tested in the reference article [13] and represented below. In this article, the antibacterial activity of the ADS-2 compound against Staphylococcus aureus is evaluated in vivo according to a protocol analogous to that detailed above. The results presented demonstrate that 30 minutes after the application of an ointment based on the compound ASD-2, the bacterial count is identical to that obtained with the control group. The compound ASD-2, unlike the compound (5) according to the invention, does not make it possible to significantly reduce the initial bacterial count in just 30 minutes.

4. Cytotoxicity

The toxicity of the compounds (1), (2), (3) and (5) synthesized above on Chinese hamster ovary cells (CHO cells for Chinese Hamster Ovary) is evaluated according to the protocol defined above. below.

Protocol:

CHO cells are seeded in a 24-well plate with a concentration of 80,000 cells / well in 500 μL of fresh medium containing fetal calf serum (SVF) then incubated for 16 h at 37 ° C. under a humid atmosphere comprising 5% by volume of carbon dioxide C0 ₂ .

After incubation, the cells are treated with one of the compounds (1), (2), (3) or (5) synthesized above with and without metabolic bioactivation (S9). The toxicity of each of the compounds, with and without cell bioactivation, is evaluated at 3 different concentrations. 3 wells per concentration and per test compound are made so as to obtain 3 series of results.

A negative control (solvent) and a positive control were also included.

The cells are then placed for 3 h at 37 ° C. in a humid atmosphere comprising 5% by volume of carbon dioxide CO ₂ .

After exposure, cell viability is measured using an automated cell viability counter (Luna FL®).

Results:

The results obtained are presented in Table 4 below.

Table 4: Viability of CHO cells exposed to different concentrations of compounds (1), (2), (3) and (5) with and without metabolic bioactivation (S9)

In the absence of metabolic activation

The tests carried out at a concentration equal to 0.5 or 1 pg / n μl do not make it possible to discriminate the different compounds.

At a concentration equal to 5 pg / mL, a toxicity of the order of 35% is observed for the compound (1), while a toxicity less than 12%, or even an absence of toxicity, is observed with the compounds (2), (3) and (5).

With metabolic activation

The tests carried out at a concentration equal to 1 or 5 pg / m L do not make it possible to discriminate the different compounds.

At a concentration equal to 10 pg / m L, a toxicity of the order of 30% is observed for the compound (1), while a toxicity less than 5%, or even an absence of toxicity, is observed with the compounds (2), (3) and (5).

These results thus show that the compounds (2), (3) and (5) exhibit cytotoxicity on CHO cells significantly lower than that of the compound (1).

BIBLIOGRAPHY

(1) World Health Organization (WHO), Tuberculosis [internet link]

Available at:

http://www.who.int/fr/news-room/fact-sheets/detaiiytuberculosis

(2) Mjid M, Cherif J, Ben Salah N, Toujani S, Ouahchi Y, Zakhama H, et al.

Epidemiology of tuberculosis. Rev Pneumol Clin. 2015 Apr l; 7l (2— 3): 67—72.

(3) Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. Campion EW, editor. N Engl J Med. 2015 May 28; 372 (22): 2127-35.

(4) Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN, McCrimmon D, et al.

Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A. 1993 Feb 15; 90 (4): 1354-8.

(5) Alhanout K, Malesinki S, Vidal N, Peyrot V, Rolain JM, Brunel JM. New insights into the antibacterial mechanism of action of squalamine. J Antimicrob Chemother. 2010 Aug l; 65 (8): 1688-93.

(6) Alhanout K, Djouhri L, Vidal N, Brunel JM, Piarroux R, Ranque S. In vitro activity of aminosterols against yeasts involved in blood stream infections. Med Mycol. 2011 Feb; 49 (2): 121-5.

(7) Brunel J-M, Raoult D, Rolain J-M. Aminosteroid compounds for local topical application for skin and mucosal decolonization of Staphylococcus aureus. EP2506856 A1, 2012.

(8) Djouhri-Bouktab L, Vidal N, Rolain JM, Brunel JM. Synthesis of new 3,20- bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. J Med Chem. 2011 Oct; 54 (20): 74l7-2l.

(9) Ghodbane R, Ameen SM, Drancourt M, Brunel JM. In vitro antimicrobial activity of squalamine derivivatives against mycobacteria. Tuberculosis. 2013 Sep; 93 (5): 565-6.

(10) Walker BT, Houston TA. Squalamine and its derivatives as potential antitubercular compounds. Tuberculosis. 2013 Jan; 93 (l): 102-3.

(11) Asmar S, Drancourt M. Chlorhexidine decontamination of sputum for culturing Mycobacterium tuberculosis. BMC Microbiol. 2015 Aug 5; 15: 155. (12) Astagneau P, Desplaces N, Vincent V, Chicheportiche V, Botherel A, Maugat S, et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet (London, England). 2001 Sep 1; 358 (9283): 747-51.

(13) Djouhri-Bouktab L. et al. Squalamine oinment for Staphylococcus aureus skin decolonization in a mouse model. Journal of Antimicrobial Chemotherapy, 2011, 66: 1306-1310

Claims

1. Compound chosen from:

- the compounds of formula (P) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group; an aryl group in

C ₆ -Ci ₂ ,

- the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ -NHR _S _I0 with s an integer ranging from 1 to 5 and Rio a hydrogen atom, a Ci-Ci ₂ alkyl group or a C ₆ -Ci ₂ aryl group, and

- The groups R§ and R ₉ , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group or R§ and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

- the Ru and R groups _{| 2} , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group, m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit -

[X- (CR ₅ R6) m] -,

2. Compound for its use according to claim 1, said compound being chosen from:

- the compounds of formula (I) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

C ₆ -Ci ₂ ,

- The groups R§ and R ₉ , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group or R§ and R ₉ form together a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

- The groups Ru and R _I2 , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit - [X- (CR ₅ R6) m] -.

3. Compound for use according to any of

claims 1 and 2, in which the bacteria responsible for the infection is chosen from Mycobacterium tuberculosis, Mycobacterium africanum,

Mycobacterium abscessus, Mycobacterium massiliense, Mycobacterium chelonae, Mycobacterium immunogenum, Mycobacterium bolletii,

Mycobacterium avium avium, Mycobacterium avium intracellulare,

Mycobacterium avium hominissuis and Mycobacterium xenopi, preferably chosen from Mycobacterium tuberculosis and Mycobacterium africanum, even more preferably st Mycobacterium tuberculosis.

4. Compound for use according to any of

Claims 1 to 3, said compound being chosen from the compounds of formula (1), (2), (3), (4) or (5) below:

(2)

5. Use of a compound as defined in any one of claims 1, 2 and 4 as a disinfectant and / or decontaminant of an inert material object against contaminating agents chosen from mycobacteria.

6. Compound chosen from sulphate and / or dichloroacetate salts of the compounds of formula (P) below:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

7. Compound according to claim 6, said compound being chosen from the sulphate and / or dichloroacetate salts of the compounds of formula (I) below:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

C ₆ -Ci ₂ ,

8. Compound according to any one of claims 6 and 7, said compound being chosen from the compounds of formula (2) or (3) below:

9. Compound chosen from:

- the compounds of formula (P) below, and

- their pharmaceutically acceptable salts,

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -,

the groups R ₃ to R _f , which are identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group; an aryl group in

C ₆ -C ₁₂ , - the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ _S - NHRio with s an integer ranging from 1 to 5 and a Rio hydrogen atom, a C1-C12 alkyl group or a C ₆ -C ₁₂ aryl group, and

- The groups R§ and R ₉ , identical or different, are chosen from: a hydrogen atom; a C1-C12 alkyl group or R§ and R ₉ together form a heterocyclic group, optionally substituted, comprising from 5 to 20 atoms,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit -

[X- (CR ₅ R6) m] -,

in which at least one of the groups R§ and R ₉ is different from a hydrogen atom.

10. Compound according to claim 9 chosen from:

- the compounds of formula (I) below, and

- their pharmaceutically acceptable salts,

in which Ri and R ₂ are independently chosen from the groups of formula - (CR3R ₄ ) _n - [X- (CR5R6) _m ] _P -NR8R ₉ in which:

- n and m are integers, identical or different, ranging from 1 to 40,

- p is an integer ranging from 0 to 4,

- X is an oxygen atom or a group -NR ₇ -, the groups R ₃ to R ₆ , which are identical or different, are chosen from: a hydrogen atom; -alkyl, Ci-Ci _2; a C ₆ -C ₁₂ aryl group,

- the group R ₇ is selected, independently, from a hydrogen atom, an alkyl group Ci-C ₆ or a group - (CH ₂₎ -NHR _S _I0 with s an integer ranging from 1 to 5 and Rio a hydrogen atom, an alkyl group Ci-Ci ₂ aryl or C ₆ -C _l2, and

- The groups Ru and R ₁₂ , identical or different, are chosen from: a hydrogen atom; a Ci-Ci ₂ alkyl group,

m, X, R ₅ , R ₆ and R ₇ being chosen independently for each unit -

[X- (CR ₅ R6) m] -,

in which at least one of the groups R and R ₉ is different from a hydrogen atom.

11. Compound according to any one of claims 9 and 10, said compound being chosen from the compounds of formula (4) or (5) below:

12. Compound according to any one of claims 6 to 11, for its use as a medicament for the prevention and / or treatment

bacterial, fungal, viral, parasitic infections or the treatment of cancer in humans or animals, more preferably for the prevention and / or treatment of bacterial infections, even more preferably for the prevention or treatment of Staphylococcus aureus infections.

13. Pharmaceutical composition comprising at least:

- a compound according to any one of claims 6 to 11, and

- a pharmaceutically acceptable excipient.

14. Disinfecting and / or decontaminating composition comprising at least:

- a compound according to any one of claims 6 to 11, and

- a suitable support for an application to an inert material object.